docLatest Report: Glioblastoma Treatment Market Will Expand Fivefold to $3.3 Billion at a CAGR of 17.4% by 2024
download 
Report Transcription
Latest Report: Glioblastoma Treatment Market Will Grow at 19.7 % CAGR by 2024 The glioblastoma treatment market will increase fivefold from $659 million in 2014 to $3.3 billion by 2024, representing a rapid Compound Annual Growth Rate (CAGR) of 17.4% according to a leading research and consulting firm. Of the 7MM, Japan will see the most impressive relative growth, with sales expanding from $47 million in 2014 to $268 million in 2024, representing a CAGR of 19.7%. This report provides analysis of the glioblastoma treatment space across the seven major countries of the US, France, Germany, Italy, Spain, the UK, and Japan, including annualized market data from 2014 and forecast to 2024. It discusses strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the glioblastoma therapeutics market. Browse Detailed Toc, Tables, Figures, Charts and Companies Mentioned in Glioblastoma Treatment Market Research Report at- http://www.absolutereports.com/opportunityanalyzerglioblastoma-opportunity-analysis-and-forecasts-to-2024-10112597 The company’s latest report states that this meteoric rise, which will occur across the seven Major Markets (7MM) of the US, Spain, France, the UK, Italy, Germany and Japan, will primarily be due to the launch of new therapies for glioblastoma patients with high unmet needs. Although glioblastoma is a rare disease, such high levels of unmet need in the market have created ample opportunities for players with effective therapies. However, developing drugs which effectively treat glioblastoma has proved exceedingly challenging to date, predominantly due to the presence of the blood-brain barrier, which prevents many drugs from entering the brain and attacking the tumor. Ask for Discount on Glioblastoma Treatment Market Research Report at – http://www.absolutereports.com/enquiry/request-discount/10112597 With the rest of the 7MM excluding Japan, growth will be driven by the introduction of new drugs such as Opdivo. However, higher pricing of the drug in Japan will result in the country’s even faster growth rate, according to a leading research firm. Current pipeline drugs offer potential solutions to this complex obstacle, and has identified BristolMyers Squibb’s immunotherapy Opdivo (nivolumab) as a particular contender to become the primary standard of care by 2024. +1 408 520 9750 www.absolutereports.com Request sample PDF of this report at - http://www.absolutereports.com/enquiry/requestsample/10112597 This report will enables - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list. - Develop business strategies by understanding the trends shaping and driving the global GBM therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global GBM therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Track drug sales in the global GBM therapeutics market from 2014-2024. - Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. About Absolute Report: Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters. Contact– Mr. Ameya Pingaley Absolute Reports +1-408 520 9750 Email – [email protected] Website: www.absolutereports.com +1 408 520 9750 www.absolutereports.com
Similar documents
Medtronic plc, Bioventus LLC and Depuy Companies Dominate the UK Orthobiologics Market Report
The orthobiologics market in the UK is expected to be driven by patient demographics, the development of novel product designs, increasing patient awareness, increasing participation in sports related activities, and a rising incidence of road accidents. The data in the report is derived from dynamic market forecast models.
First Electric Cooperative Corporation, Update 2015
The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executives), and major products and services.
France Orthopedic Prosthetics Procedure report to 2021, Market Shares, Research Report, Industry Analysis, Forecast Opportunity
prosthesis is a functional replacement for an amputated or congenitally malformed or missing limb. Prosthetists are responsible for the prescription, design and management of a prosthetic device. In most cases, the prosthetist begins by taking a plaster cast of the patient's affected limb. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market segments - Lower Extremity Prosthetics and Upper Extremity Prosthetics.
Ventricular Fibrillation: Global Industry Analysis, Trends, Market Demands, Segment and Forecast
Ventricular Fibrillation- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India.
Latest Research Report on Medical Equipment Monthly Deals Analysis: JANUARY 2016 - M&A and Investment Trends
Medical Equipment Monthly Deals Analysis: JANUARY 2016 report provides detailed information on M&As, equity/debt offerings, private equity, venture financing and partnership transactions registered in the medical equipment industry in January 2016.
Human Immunodeficiency Virus (Hiv) Therapeutics Market Worth Will Be $15 billion in Sales by 2023
The global HIV therapeutics market was worth approximately $14 billion in 2013, and it is expected to rise a total of $15 billion in sales by 2023, at a Compound Annual Growth Rate (CAGR) of 0.9%. These sales are expected to come predominantly from the US market, as financial austerity measures remain a primary barrier to the growth of the HIV market in the other countries covered in this report.
Hepatitis B Virus (HBV) Therapeutics Market to Expand at a modest Compound Annual Growth Rate (CAGR) of 2.4% Up to 2024
The global hepatitis B market, which is set to experience limited growth from $2.4 billion in 2014 to $3 billion by 2024, is being stymied by the persistence of low diagnosis and treatment rates, according to research. Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains a serious global health concern, with estimated over 350 million people worldwide currently living with this condition.
Recent Research: Respiratory Syncytial Virus Treatment Market Will Surpass $2.3 Billion by 2024
According to a leading research and consulting firm, The Global Respiratory Syncytial Virus (RSV) treatment market will expand to unprecedented levels over the next decade, rising from approximately $640 million in 2014 to over $2.3 billion by 2024, representing an impressive Compound Annual Growth Rate (CAGR) of 29.9%.
Hodgkin Lymphoma Market 10 Year Epidemiology Forecasts in 7 Major Markets
The Hodgkin’s lymphoma treatment market is set to increase more than fourfold from $316 million in 2014 to $1.4 billion by 2024, representing a Compound Annual Growth Rate (CAGR) of 16%. Hodgkin’s lymphoma (HL), or Hodgkin’s disease, is a malignancy which involves the lymph nodes and the lymphatic system. HL is a relatively rare type of cancer, accounting for 12% of all lymphomas and 0.6% of all new cancer cases, but overall prognosis is very good.
Latest Research: US Will Remain Hernia Repair Market Leader by 2021
The overall US hernia repair market is expected to rise to approximately $1.2 billion by 2021, at a moderate Compound Annual Growth Rate (CAGR) of 4%. It was valued at approximately $875 million in 2014. The US has a higher adoption of expensive meshes in general, and procedure volume will go up by 1% annually. For example, the majority of umbilical hernia repairs are performed with composite meshes, which contribute to a higher market valuation.
Pulmonary arterial hypertension market to generate sales of approximately $4.75 billion by the end of 2024
The Pulmonary Arterial Hypertension (PAH) therapeutics market will experience modest growth from $3.45 billion in 2014 to $4.75 billion by 2024, representing a Compound Annual Growth Rate (CAGR) of 3.2%.This report on the global pulmonary arterial hypertension (PAH) market offers an insightful and in-depth assessment of the current and future market potential of PAH drugs.
UK Hip Reconstruction Market Forecast till 2021: Present and Future Trends and Growth Opportunities
The report firstly introduced the HIP Reconstruction basics: definitions, classifications, applications and industry chain overview; industry policies and plans; product specifications; manufacturing processes; cost structures and so on. The data includes market size in terms of value and volume; average selling price for each product type, growth trends and market shares of companies at sector and category level.
Gaucher Disease (GD) - Market Insights, Epidemiology and Market Forecasts, 2024
The Report,” Gaucher Disease - Epidemiology Forecast to 2024" market research providing an overview of the risk factors and global trends of GD in the 7MM US, France, Germany, Italy, Spain, UK, and Israel. It includes a 10-year epidemiology forecast for the total prevalent cases of Type 1, 2, and 3 GD, segmented by age and sex in these markets. GD epidemiology report is written and developed by Masters- and PhD-level epidemiologists. The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Diagnosed Prevalent Cases of Fabry Disease in The 7MM Will Rise at an AGR of 7.71% By 2024
The report,” Fabry Disease - Epidemiology Forecast to 2024 “provides an overview of the risk factors, comorbidities/manifestations, and the global and historical epidemiological trends for Fabry disease in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK and Japan). It also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of Fabry disease in these markets, segmented by age and sex.
- Latest Innovations, Drivers, Restraints, Challenges and Key Events in the industry by 2024
Alcohol consumption and malaria are the possible risk factors for the development of GBM. In addition, neurofibromatosis, tuberous sclerosis, von-hippel-lindau disease, Li-fraumeni syndrome and turcot syndrome are some of the genetic disorders that are associated with increasing incidences of gliomas. Glioblastoma multiforme is a World Health Organization Grade IV tumor that represents 15 to 20% of all primary intracranial tumors.